CA2249733A1 - Inhibiteurs de l'integrine spirocycle - Google Patents
Inhibiteurs de l'integrine spirocycle Download PDFInfo
- Publication number
- CA2249733A1 CA2249733A1 CA002249733A CA2249733A CA2249733A1 CA 2249733 A1 CA2249733 A1 CA 2249733A1 CA 002249733 A CA002249733 A CA 002249733A CA 2249733 A CA2249733 A CA 2249733A CA 2249733 A1 CA2249733 A1 CA 2249733A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- aminomethyl
- oxa
- carbonylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne de nouveaux hétérocycles, comprenant l'acide (S)-2-phénylsulfonylamino-3[8-(2-pirydinilaminométhyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionique, qui sont utiles en tant qu'antagonistes de l'intégrine .alpha.¿v?.beta.¿3? et les récepteurs apparentés de protéines adhérant à la surface de cellules, l'invention concernant également des compositions pharmaceutiques contenant ces composés, des procédés de préparation de ces composés, ainsi que des méthodes d'utilisation de ces composés, seuls ou combinés à d'autres agents thérapeutiques pour empêcher l'adhésion cellulaire, le traitement de troubles angiogéniques, l'inflammation, la dégradation osseuse, les métastases de cancer, la rétinopathie diabétique, la thrombose, la resténose, la dégénération maculaire et d'autres états pathologiques induits par l'adhésion cellulaire et/ou la migration cellulaire et/ou l'angiogenèse.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1353996P | 1996-03-15 | 1996-03-15 | |
US60/013,539 | 1996-03-15 | ||
US64689696A | 1996-05-08 | 1996-05-08 | |
US08/646,896 | 1996-05-08 | ||
US08/816,580 US5760029A (en) | 1996-03-15 | 1997-03-14 | Spirocycle integrin inhibitors |
US08/816,580 | 1997-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2249733A1 true CA2249733A1 (fr) | 1997-09-18 |
Family
ID=27359885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002249733A Abandoned CA2249733A1 (fr) | 1996-03-15 | 1997-03-17 | Inhibiteurs de l'integrine spirocycle |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0888344A1 (fr) |
JP (1) | JP2001527513A (fr) |
AU (1) | AU2421797A (fr) |
CA (1) | CA2249733A1 (fr) |
WO (1) | WO1997033887A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214834B1 (en) | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
NZ507222A (en) | 1998-04-09 | 2003-05-30 | Meiji Seika Kaisha | Aminopiperidine derivatives useful as integrin antagonists |
ES2322723T5 (es) * | 1998-05-08 | 2013-03-11 | The Regents Of The University Of California | Métodos para detectar e inhibir la angiogénesis |
US6852318B1 (en) | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6586187B1 (en) | 1999-04-14 | 2003-07-01 | Wyeth | Methods for solid phase combinatorial synthesis of integrin inhibitors |
DE19921101A1 (de) * | 1999-05-03 | 2000-11-16 | Schering Ag | Neue spirocyclische Verbindungen, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung hyperproliferativer Erkrankungen |
CN1374863A (zh) | 1999-07-21 | 2002-10-16 | 惠氏公司 | αvβ3整联蛋白的双环选择性拮抗剂 |
US6750219B1 (en) | 1999-08-05 | 2004-06-15 | Meiji Seika Kaisha, Ltd. | Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity |
DE10130020A1 (de) * | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
US7285268B2 (en) | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US7276589B2 (en) | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
BRPI0509177A (pt) | 2004-03-24 | 2007-09-18 | Pdl Biopharma Inc | uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas |
GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
DE102005044813A1 (de) * | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005023784A1 (de) * | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005044814A1 (de) * | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
EP1739078A1 (fr) | 2005-05-30 | 2007-01-03 | Jerini AG | Antagonistes du recepteur C5a |
GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
JP6480653B2 (ja) * | 2013-09-26 | 2019-03-13 | 株式会社トーキン | 導電性高分子溶液 |
JP6650942B2 (ja) | 2014-12-17 | 2020-02-19 | ピムコ 2664 リミテッド | N−(4−ヒドロキシ−4−メチル−シクロへキシル)−4−フェニル−ベンゼンスルホンアミド化合物、及びn−(4−ヒドロキシ−4−メチル−シクロへキシル)−4−(2−ピリジル)−ベンゼンスルホンアミド化合物、ならびにこれらの治療上の使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294713A (en) * | 1991-08-23 | 1994-03-15 | Takeda Chemical Industries, Ltd. | 2-piperazinone compounds and their use |
PL182303B1 (en) * | 1993-11-24 | 2001-12-31 | Du Pont Pharm Co | Novel derivatives of isoxazoline and isoxazole having properties of fibrinogen receptor antagonists |
NZ276631A (en) * | 1993-11-24 | 1997-06-24 | Du Pont Merck Pharma | Isoxazoline derivatives and medicaments |
IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
-
1997
- 1997-03-17 EP EP97919892A patent/EP0888344A1/fr not_active Withdrawn
- 1997-03-17 AU AU24217/97A patent/AU2421797A/en not_active Abandoned
- 1997-03-17 JP JP53292497A patent/JP2001527513A/ja active Pending
- 1997-03-17 WO PCT/US1997/004567 patent/WO1997033887A1/fr not_active Application Discontinuation
- 1997-03-17 CA CA002249733A patent/CA2249733A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001527513A (ja) | 2001-12-25 |
AU2421797A (en) | 1997-10-01 |
WO1997033887A1 (fr) | 1997-09-18 |
EP0888344A1 (fr) | 1999-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5760029A (en) | Spirocycle integrin inhibitors | |
CA2249733A1 (fr) | Inhibiteurs de l'integrine spirocycle | |
US6153628A (en) | 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as αv β3 antagonists | |
TW454007B (en) | Novel isoxazoline and isozazole fibrinogen receptor antagonists | |
US6130231A (en) | Integrin receptor antagonists | |
EP0730590B1 (fr) | antagonistes de recepteur de fibrinogene, a base d'isoxazoline et d'isoxazole | |
AU5876296A (en) | Isoxazoline and isoxazole derivatives as integrin receptor antagonists | |
US5710159A (en) | Integrin receptor antagonists | |
WO1995018111A1 (fr) | Composes contenant des terminaisons basiques et acides utiles en tant qu'antagonistes des recepteurs de fibrinogene | |
US20020082253A1 (en) | Novel isoxazoline fibrinogen receptor antagonists | |
HRP960234A2 (en) | Novel integrin receptor antagonists | |
MXPA00005155A (en) | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS&agr;v | |
MXPA99004891A (en) | Novel integrin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |